Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States.

ABSTRACT:

Background

Monovalent booster/additional doses of COVID-19 vaccines were first authorized in August 2021 in the United States. We evaluated the real-world effectiveness of receipt of a monovalent booster/additional dose of COVID-19 vaccine compared with receiving a primary vaccine series without a booster/additional dose.

Methods

Cohorts of individuals receiving a COVID-19 booster/additional dose after receipt of a complete primary vaccine series were identified in 2 administrative insurance claims databases (Optum, CVS Health) supplemented with state immunization information system data between August 2021 and March 2022. Individuals with a complete primary series but without a booster/additional dose were one-to-one matched to boosted individuals on calendar date, geograph

SUBMITTER: Layton JB 

PROVIDER: S-EPMC10840109 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature